1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Dravet Syndrome (DS) - Market Insights, Epidemiology and Market Forecast-2028

Dravet Syndrome (DS) - Market Insights, Epidemiology and Market Forecast-2028

  • August 2019
  • 120 pages
  • ID: 5805127
  • Format: PDF
  • By Delve Insight

Summary

Table of Contents

‘Dravet Syndrome (DS) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of DS in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom),Japan, Australia and Austria.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Dravet Syndrome (DS) from 2017 to 2028 segmented by nine major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
• Australia
• Austria
Study Period: 2017-2028
Dravet Syndrome (DS) - Disease Understanding and Treatment Algorithm
Dravet Syndrome (DS) market report gives the thorough understanding of the Dravet Syndrome by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Dravet Syndrome in the US, Europe, Japan, Australia and Austria.
Dravet Syndrome Epidemiology
The Dravet Syndrome (DS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 9 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total incident population, incidence of Dravet Syndrome by Mutation Class, incidence of Dravet Syndrome by Mutation Type, seizure associated cases, gender-specific incident cases and age-specific incident cases) scenario of Dravet Syndrome (DS) in the 9MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan, Australia and Austria from 2017-2028.
According to the analyst, the total number of prevalent cases of Dravet Syndrome (DS) in 7 MM was found to be 36,301, in the year 2017.

Dravet Syndrome Drug Chapters
This segment of the Dravet Syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The market forecast solely focuses on the market revenue generated by the pharmacological treatment. Pharmacological management of Dravet syndrome focuses largely on the use antiepileptic drugs such as Valproic Acid, Clobazam, Topiramate, Levetiracetam, Zonisamide and Stiripentol. Detailed chapter for upcoming therapies like ZX008 (Zogenix) have been covered in the report.
Dravet Syndrome Market Outlook
The Dravet Syndrome market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the analyst, the market of Dravet Syndrome in 9MM was found to be USD 112.88 million in 2017, and is expected to increase at a CAGR of XX% from 2017-2028.
Dravet Syndrome Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Dravet Syndrome Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Dravet Syndrome Report
Key strengths

• 10 Year Forecast
• 9MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Dravet Syndrome Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This report will help to develop Business Strategies by understanding the trends shaping and driving Dravet Syndrome market
• Organize sales and marketing efforts by identifying the best opportunities for Dravet Syndrome market
• To understand the future market competition in the Dravet Syndrome market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Tourette Syndrome - Pipeline Review, H2 2019

Tourette Syndrome - Pipeline Review, H2 2019

  • $ 2000
  • August 2019

Tourette Syndrome - Pipeline Review, H2 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome - Pipeline Review, H2 2019, provides an overview ...

Hepatic Encephalopathy - Pipeline Review, H2 2019

Hepatic Encephalopathy - Pipeline Review, H2 2019

  • $ 2000
  • August 2019

Hepatic Encephalopathy - Pipeline Review, H2 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Pipeline Review, H2 2019, provides ...

Restless Legs Syndrome - Pipeline Review, H2 2019

Restless Legs Syndrome - Pipeline Review, H2 2019

  • $ 2000
  • August 2019

Restless Legs Syndrome - Pipeline Review, H2 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Pipeline Review, H2 2019, provides ...


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on